A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study With Additional Multiple-Ascending Dose Cohorts to Evaluate the Safety, Tolerability and Pharmacokinetics of TKM-100201 in Healthy Human Volunteers.

Trial Profile

A Placebo-Controlled, Single-Blind, Single-Ascending Dose Study With Additional Multiple-Ascending Dose Cohorts to Evaluate the Safety, Tolerability and Pharmacokinetics of TKM-100201 in Healthy Human Volunteers.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 26 Nov 2015

At a glance

  • Drugs TKM Ebola (Primary)
  • Indications Ebola virus infections
  • Focus Adverse reactions
  • Sponsors Arbutus Biopharma
  • Most Recent Events

    • 07 May 2015 According to Tekmira Pharmaceuticals media release, initiation of re peat dosing cohort is planned for second quarter of 2015 and the study will be funded by the U.S. Department of Defence.
    • 01 Jan 2014 Status changed from recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 06 Sep 2012 The US Department of Defense has extended the stop-work order for Tekmira's ebola virus programme.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top